Therapy for the reversal of Type I Diabetes
Combination treatment of Ig-GAD2 and stem cells to cure Type I Diabetes (TID). Data demonstrate a functional cure in a mouse model for TID through restoration of immune tolerance coupled with regeneration of endothelial cells in the pancreatic islets. Patents issued and pending.
Researchers at the University of Missouri-Columbia have developed a novel method to treat type I diabetes (T1D). While insulin is necessary for survival, it does not treat the disease. The inventors had previously shown that an Ig-GAD2 regimen given to non-obese diabetic mice prevented disease progression. By accompanying their previous methods with the transfer of bone marrow cells from healthy donors, researchers were able to induce immune modulation of islet inflammation, repair islet vasculature and sustain regeneration and function of insulin-producing cells, leading to the reversal of overt T1D. While the bone marrow cells gave rise to the endothelial cells in the pancreas, the new β-cells were of host origin. Also, the treatment ablated insulin-resistance associated with the onset of T1D. Thus, overcoming T1D requires both immune modulation and repair of the vascular niche to preserve the newly formed β-cells.